
Kolibri Q3 revenue hits $18.3M, up 22%
Key points
- Kolibri Global Energy (NASDAQ:KGEI; TSX:KEI) reported third-quarter 2026 revenue, net of royalties, of US$18.3 million, up 22% year over year, while year-to-date production increased 15% and net revenues rose 43%.
- Adjusted EBITDA increased 20% to US$13.3 million, while net income remained unchanged at US$3.6 million.
- The company is expanding production through new wells in Oklahoma, with its credit facility maintaining a US$75 million borrowing base and US$19.5 million in available borrowing capacity at September 30.
Kolibri Global Energy (NASDAQ:KGEI) reported third-quarter 2026 revenue, net of royalties, of US$18.3 million, up 22% from US$15 million a year earlier, driven by a 34% increase in average prices.
The company maintained net income of US$3.6 million, or US$0.10 per basic share, compared with the same figures in the third quarter of 2025, while adjusted EBITDA increased 20% to US$13.3 million from US$11.1 million.
Average production declined 9% to 3,867 barrels of oil equivalent per day (BOEPD) from 4,254 BOEPD, as temporary well shutdowns during drilling and completion operations affected output alongside normal production declines.
The quarter included a US$1 million realized loss and a US$2.4 million unrealized loss on commodity contracts, compared with a US$500,000 unrealized loss in the prior-year quarter, while production and operating expenses increased 14% to US$8.39 per barrel of oil equivalent.
Average netback from operations increased 41% to US$43.48 per BOE, while netback including commodity contracts rose 31% to US$40.55 per BOE, reflecting higher realized commodity prices.
Year-to-date production increased 15% and net revenues rose 43%, while the company maintained its US$75 million credit facility borrowing base, with US$19.5 million in available borrowing capacity at September 30, as it continued developing its Tishomingo field.
Frequently asked questions
More from United States
Zai Lab antibody shows sustained biomarker suppression in phase 1 trial
Sigma Lithium posts $22.3 million gross revenue
Milestone Pharmaceuticals cuts costs 30%, extends runway
Merck gains EU backing after 26% risk reduction
Merck gains EU backing for 24-month RSV use
Zevra receives negative EU opinion on arimoclomol